A B S T R A C T Prostacyclin (PGI2) is the most potent, naturally occurring inhibitor of platelet aggregation known. To determine whether PGI2 is bound by platelets, high specific activity [9-3H]PGI2 was synthesized by iodination and subsequent base treatment of the labeled precursor [9-3H]prostaglandin (PG)F, methyl ester. Binding experiments were performed at room temperature with normal citrated human platelet-rich plasma that contained [14C]sucrose or ['4C]PGF,l< as an internal marker for the extracellular space. Binding of [3H]PGI2 plateaued within 2 min and this bond radioactivity could be displaced rapidly by excess nonradioactive PGI2. Scatchard analysis of concentration-dependent binding yielded a hyperbolic plot which appeared to be caused by the existence of two classes of binding sites. The higher affinity class has a dissociation constant of 12.1±2.7 nM and a capacity of 93 (±21)sites per platelet. The lower affinity class had a dissociation constant of 0.909±t.236 ,uM and a capacity of 2,700+700 sites per platelet. The relative ability of PGI2, PGE1, PGE2, and 6-keto-PGFi,a to displace
INTRODUCTION
Until recently, the most potent inhibitor of platelet aggregation known was prostaglandin (PG)E,l (1) . In This work has been published in abstract form in 1978. Fed. Proc. 37: 260.
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1974, PGD2 was found to be more potent as an inhibitor of human platelet aggregation although it was relatively inactive on platelets-obtained from other species (2) . In 1976, Moncada et al. (3) discovered an even more potent but unstable inhibitor of platelet aggregation which was produced from prostaglandin endoperoxides by an enzyme present in blood vessels. They proposed that the continuous synthesis of this substance protects arterial walls against the deposition of platelet thrombi (4) . The structure of this inhibitor has been determined and it is now known as prostacyclin (PGI2) (5) . Cultured endothelial cells possess the capacity to synthesize PGI2 (6, 7) . It inhibits the aggregation of platelets from all species examined (8, 9) .
PGE1, PGD2 and PGI2 have been shown to activate adenylate cyclase and increase cyclic (c)AMP levels in human platelets (1, (10) (11) (12) . Tateson et al. (12) demonstrated that PGI2 at 10 nM caused an increase in cAMP levels equivalent to five times the basal level, whereas it required 1 uM PGD2 to acheive this increase. The stimulation of adenylate cyclase by PGI2 argues for its interaction with a specific membrane-bound receptor system similar to that involved in the f-adrenergic system (13) . We describe here the properties of a binding site for PGI2 on intact platelets, which appears to be its specific membrane receptor. Fig. 2 . A curvilinear plot was obtained when values were plotted over the complete concentration range. This curve was a hyperbola, because a straight line (correlation coefficient, 0.996) was obtained when the same data was plotted on double log paper. The two asymptotes to this hyperbola (the product of which describes the hyperbola) were derived by iterative geometric construction (Fig. 2, dashed lines) . It was assumed that the hyperbola reflected the binding of [3H]PGI2 to two independent sites with different affinities and the asymptotes were used to derive the dissociation constants for each of these sites (15 (Table I) and therefore we justified all conclusions reached with sucrose as the marker by also using [14C]PGF,0,,.
As shown in Fig. 1 , the binding of PGI2 by platelets was rapid and 80% of the binding was complete by 1 min. The effects of PGI2 on aggregation and increases in platelet cAMP occur within this same time (11, 12) , suggesting that binding is associated with almost immediate activation of adenylate cyclase. The rapid displacement of bound [3H]PGI2 by unlabeled PGI2 (Fig. 1) shows that binding was reversible and suggests that PGI2 is bound at an extracellular site. It previously has been shown that E-and F-type prostaglandins do not equilibrate across membranes in the absence of an active transport system (17) . This is consistent with our findings that the plasma spaces determined with [14C]sucrose and [14C]PGF10 were identical ( Table I) .
The concentration-dependent aspects of PGI2 binding were complex as a hyperbolic plot was obtained on Scatchard analysis (Fig. 2) . We assumed that this data reflected the binding of [3H]PGI2 to two independent sites with different affinities. An alternative explanation could be that negative cooperativity is involved (18) .
The dissociation constant (12.1 nM) of the higher affinity binding site for PGI2 is of the same order of magnitude as that found by other investigators studying prostaglandin binding in several other biological systems (16, 19) although it is fourfold higher than the value obtained for 50% inhibition of platelet aggregation (3.4 nM). However, a direct constant is a measure of the direct physical interaction of PGI2 with its receptor, whereas the effective dose for 50% inhibition ofaggregation reflects complex interactions involv- ing elevation (and sometimes reductions) of cAMP (20) . As shown in Fig. 2 (11) . That reported to half maximally stimulate adenyl cyclase in platelet membranes was 28 nM (12) . These values differ by a factor of from 2 to 10 from the dissociation constant we obtained for the higher affinity site. These differences may reflect the fact that cyclic AMP measurements over short time periods are not equilibrium measurements and do not accurately measure PGI2 activation of adenyl cyclase. The structural specificity of prostaglandin binding was investigated by testing the ability of several unlabeled prostaglandins to displace [3H]PGI2 initially bound to the higher affinity site on platelets (Fig. 3) . The concentration of PGI2 required to displace 50% of this bound radioactivity was 0.3 ,uM. As expected, this value lay between the dissociation constants for the lower and higher affinity sites because some of the radioactivity displaced from the higher affinity sites reequilibrated with the large number of lower affinity sites during the 10-min incubation period. PGE, also displaced bound [3H]PGI2 although it was only 5% as active as PGI2 itself. The remainder of prostaglandins, including PGD2 were <0.3% as effective as PGI2. PGI2 is unstable at neutral pH and spontaneously converts to 6-keto-PGFse. Because 6-keto-PGF,s, was almost incapable of displacing bound radioactivity, it is unlikely that the binding of 6-keto-PGF,e was a factor in our measurements.
With the exception of PGD2, the results of these displacement experiments correlate well with the relative potencies obtained in the aggregation experiments. PGD2 did not displace bound PGI2 but was approximately twice as active as PGE1 as an inhibitor of aggregation (7% as effective as PGI2). PGD2 also increases cAMP in platelets and its potency, relative to PGE1 and PGI2, correlates well with its ability to inhibit aggregation (12) . Previous to the discovery of PGI2, Mills and Macfarlane (10) suggested that PGE, and PGD2 may act on different receptors on platelets because of subtle differences noted in the time-course of increases in cAMP produced by these two prostaglandins. Subsequently, based on measurements of platelet cAMP, they suggested that PGE, and PGI2 act on the same receptor, whereas PGD2 acts on another (21, 22 In conclusion, we have described a high-affinity binding site for PGI2 on platelets that fulfills most of the necessary criteria for a specific receptor. Our results indicate that PGD2 does not occupy this receptor. It will be of interest to determine whether platelets of patients with thrombotic tendencies have a diminished number of binding sites for PGI2.
